[go: up one dir, main page]

AR036727A1 - Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento - Google Patents

Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento

Info

Publication number
AR036727A1
AR036727A1 ARP020103739A ARP020103739A AR036727A1 AR 036727 A1 AR036727 A1 AR 036727A1 AR P020103739 A ARP020103739 A AR P020103739A AR P020103739 A ARP020103739 A AR P020103739A AR 036727 A1 AR036727 A1 AR 036727A1
Authority
AR
Argentina
Prior art keywords
hepatitis
manufacture
composition
pharmaceutical compositions
reduce
Prior art date
Application number
ARP020103739A
Other languages
English (en)
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AR036727A1 publication Critical patent/AR036727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Power Sources (AREA)

Abstract

Composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de IFN-alfa e IFN-gama concurrentemente destinadas para reducir la fibrosis hepática; métodos para aumentar la función hepática en un individuo que sufre de fibrosis hepática; métodos para reducir la incidencia de complicaciones asociadas con VHC y cirrosis del hígado; para reducir la carga viral, y métodos para tratar una infección de VHC y uso de dicha composición para la manufactura de una medicamento para reducir la fibrosis hepática o para lograr una respuesta viral sostenida destinada para tratar una infección causada por el virus de la hepatitis C.
ARP020103739A 2001-10-05 2002-10-03 Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento AR036727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32774301P 2001-10-05 2001-10-05

Publications (1)

Publication Number Publication Date
AR036727A1 true AR036727A1 (es) 2004-09-29

Family

ID=23277847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103739A AR036727A1 (es) 2001-10-05 2002-10-03 Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento

Country Status (15)

Country Link
US (1) US20050013801A1 (es)
EP (1) EP1450848A4 (es)
JP (1) JP2005508935A (es)
KR (1) KR20050033518A (es)
CN (1) CN1564693A (es)
AR (1) AR036727A1 (es)
BR (1) BR0213093A (es)
CA (1) CA2460341A1 (es)
HU (1) HUP0600449A2 (es)
IL (1) IL161022A0 (es)
MX (1) MXPA04003239A (es)
NO (1) NO20041815L (es)
PL (1) PL371683A1 (es)
WO (1) WO2003030613A2 (es)
ZA (1) ZA200402353B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006033453A1 (ja) * 2004-09-22 2006-03-30 Juntendo Educational Foundation インターフェロン作用物質の活性増強剤
KR20090037347A (ko) * 2007-10-10 2009-04-15 한올제약주식회사 ＨＭＧ－ＣｏＡ 환원효소억제제와 담즙산을 포함하는 Ｃ형 간염 치료용 약학조성물
JP6632802B2 (ja) * 2012-01-16 2020-01-22 マッケンナ，エリザベス 肝疾患及び肝障害を治療するための組成物及び方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462986A (en) * 1982-11-04 1984-07-31 Ens Bio Logicals, Inc. Synergistic anti-herpes compositions
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
US5082659A (en) * 1986-10-06 1992-01-21 Board Of Regents, The University Of Texas System Methods and compositions employing interferon-gamma
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5190751A (en) * 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
WO1988009673A1 (en) * 1987-06-02 1988-12-15 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
ATE174514T1 (de) * 1989-01-23 1999-01-15 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5141735A (en) * 1990-06-18 1992-08-25 Hoffman-La Roche, Inc. Substituted amino-benzodiazepines having anitviral activity
TW224053B (es) * 1991-09-13 1994-05-21 Paul B Chretien
JPH07503851A (ja) * 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
US5565558A (en) * 1994-12-30 1996-10-15 Mccully; Kilmer S. Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd MEDICINES FOR HEPATITIS C AND THE USE THEREOF
KR20020020809A (ko) * 1999-08-13 2002-03-15 프리돌린 클라우스너, 롤란드 비. 보레르 페길화-인터페론-알파와 관련된 미코페놀레이트 모페틸

Also Published As

Publication number Publication date
MXPA04003239A (es) 2004-07-08
NO20041815L (no) 2004-06-11
PL371683A1 (en) 2005-06-27
EP1450848A4 (en) 2005-11-09
CA2460341A1 (en) 2003-04-17
ZA200402353B (en) 2006-03-29
KR20050033518A (ko) 2005-04-12
WO2003030613A2 (en) 2003-04-17
BR0213093A (pt) 2005-03-15
HUP0600449A2 (en) 2006-09-28
CN1564693A (zh) 2005-01-12
US20050013801A1 (en) 2005-01-20
IL161022A0 (en) 2004-08-31
EP1450848A2 (en) 2004-09-01
WO2003030613A3 (en) 2003-11-06
JP2005508935A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
WO2007047146A3 (en) Inhibitors of viral replication
UY27650A1 (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
JP2008518943A5 (es)
WO2006016930A3 (en) Methods for treating hcv infection
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
JP2007522237A5 (es)
PE20001338A1 (es) Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
CO2022008701A2 (es) Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2005067454A3 (en) Combination therapy for treating hepatitis c virus infection
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
WO2006044968A3 (en) Combination therapy for treating viral infections

Legal Events

Date Code Title Description
FA Abandonment or withdrawal